Associated Genetic Biomarkers
ERBB2 S310F is present in 0.24% of AACR GENIE cases, with bladder carcinoma, breast carcinoma, colorectal adenocarcinoma, non-small cell lung carcinoma, and bile duct carcinoma having the greatest prevalence .
ERBB2 S310F is a predictive biomarker for use of trastuzumab emtansine in patients.
There are 1 NCCN guidelines that support the use of a targeted therapy based on the presence of ERBB2 S310F.
Non-small cell lung carcinoma has the most therapies targeted against ERBB2 S310F or its related pathways .
Trastuzumab Emtansine +
Non-Small Cell Lung Carcinoma -
|Biomarker Criteria:||Predicted Response: Primary Sensitivity|
|Clinical Setting(s): Metastatic (NCCN)|
|Note: Emerging Targeted Agent for patients with HER2 mutations, per NCCN.|
Significance of ERBB2 S310F in Diseases
Non-Small Cell Lung Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.